Rafferty Asset Management, LLC G1 Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$5.17 - $16.99 $710,730 - $2.34 Million	137,472 New	137,472 $1.72 Million
Q2 2022 Aug 12, 2022	SELL	$4.04 - $8.51 $1.04 Million - $2.18 Million	-256,500 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$7.6 - $11.02 $681,142 - $987,656	-89,624 Reduced 25.89%	256,500 $1.95 Million
Q4 2021 Feb 10, 2022	BUY	$10.16 - $16.17 $1.38 Million - $2.2 Million	136,288 Added 64.95%	346,124 $3.53 Million
Q3 2021 Nov 10, 2021	BUY	$13.16 - $22.47 $1.17 Million - $2 Million	89,181 Added 73.91%	209,836 $2.82 Million
Q2 2021 Aug 10, 2021	SELL	$19.57 - $26.32 $431,361 - $580,145	-22,042 Reduced 15.45%	120,655 $2.65 Million
Q1 2021 May 10, 2021	BUY	$17.58 - $32.59 $2 Million - $3.71 Million	113,946 Added 396.32%	142,697 $3.43 Million
Q4 2020 Feb 10, 2021	SELL	$10.99 - $20.4 $437,731 - $812,532	-39,830 Reduced 58.08%	28,751 $517,000
Q3 2020 Nov 13, 2020	BUY	$11.55 - $23.75 $654,596 - $1.35 Million	56,675 Added 476.02%	68,581 $792,000
Q2 2020 Aug 07, 2020	BUY	$9.57 - $24.37 $113,940 - $290,149	11,906 New	11,906 $289,000
Q1 2020 May 15, 2020	SELL	$9.07 - $26.32 $341,467 - $990,895	-37,648 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$20.54 - $31.0 $237,380 - $358,267	-11,557 Reduced 23.49%	37,648 $995,000
Q3 2019 Nov 14, 2019	SELL	$22.78 - $40.58 $188,982 - $336,651	-8,296 Reduced 14.43%	49,205 $1.12 Million
Q2 2019 Aug 09, 2019	BUY	$16.03 - $31.1 $28,565 - $55,420	1,782 Added 3.2%	57,501 $1.76 Million
Q1 2019 May 15, 2019	BUY	$14.4 - $21.45 $802,353 - $1.2 Million	55,719 New	55,719 $925,000

3.55M

11.7K

Ticker GTHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,746,800
Market Cap $306M
Description
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.